CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 180 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2021. The put-call ratio across all filers is 0.46 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,259,123 | -26.9% | 45,753 | -9.9% | 0.00% | 0.0% |
| Q2 2023 | $1,722,389 | -4.5% | 50,763 | +1.2% | 0.00% | -33.3% |
| Q1 2023 | $1,804,469 | -20.3% | 50,152 | -1.3% | 0.00% | -25.0% |
| Q4 2022 | $2,265,404 | +60.3% | 50,828 | +1.1% | 0.00% | +100.0% |
| Q3 2022 | $1,413,000 | +2.2% | 50,283 | -1.9% | 0.00% | 0.0% |
| Q2 2022 | $1,382,000 | -21.2% | 51,270 | -0.4% | 0.00% | 0.0% |
| Q1 2022 | $1,753,000 | -19.6% | 51,457 | -8.9% | 0.00% | -33.3% |
| Q4 2021 | $2,181,000 | -28.7% | 56,457 | -0.4% | 0.00% | -25.0% |
| Q3 2021 | $3,060,000 | +69.2% | 56,683 | +4.8% | 0.00% | +100.0% |
| Q2 2021 | $1,808,000 | – | 54,079 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |